Sinopharm Group Co. Ltd. (1099.HK)
1099.HK Stock Price Chart
Explore Sinopharm Group Co. Ltd. interactive price chart. Choose custom timeframes to analyze 1099.HK price movements and trends.
1099.HK Company Profile
Discover essential business fundamentals and corporate details for Sinopharm Group Co. Ltd. (1099.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Distribution
IPO Date
23 Sept 2009
Employees
108.22K
CEO
Wanyong Lian
Description
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
1099.HK Financial Timeline
Browse a chronological timeline of Sinopharm Group Co. Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Apr 2026
Earnings released on 21 Aug 2025
EPS came in at $1.22 surpassing the estimated $1.06 by +15.09%, while revenue for the quarter reached $313.45B , missing expectations by -1.51%.
Dividend declared on 16 Jun 2025
A dividend of $0.74 per share was announced, adjusted to $0.74. The dividend was paid on 12 Aug 2025.
Earnings released on 25 Apr 2025
EPS came in at $1.14 falling short of the estimated $1.50 by -24.00%, while revenue for the quarter reached $308.27B , missing expectations by -1.96%.
Earnings released on 25 Oct 2024
EPS came in at $1.28 falling short of the estimated $1.48 by -13.51%, while revenue for the quarter reached $316.51B , missing expectations by -5.26%.
Dividend declared on 17 Jun 2024
A dividend of $0.96 per share was announced, adjusted to $0.96. The dividend was paid on 13 Aug 2024.
Earnings released on 26 Apr 2024
EPS came in at $1.76 surpassing the estimated $1.66 by +6.02%, while revenue for the quarter reached $327.19B , missing expectations by -5.12%.
Earnings released on 27 Oct 2023
EPS came in at $1.42 falling short of the estimated $1.45 by -2.07%, while revenue for the quarter reached $325.45B , beating expectations by +0.41%.
Dividend declared on 19 Jun 2023
A dividend of $0.90 per share was announced, adjusted to $0.90. The dividend was paid on 14 Aug 2023.
Earnings released on 27 Apr 2023
EPS came in at $1.75 matching the estimated $1.75, while revenue for the quarter reached $628.85B , beating expectations by +91.11%.
Earnings released on 30 Jun 2022
EPS came in at $1.39 falling short of the estimated $1.45 by -4.14%, while revenue for the quarter reached $306.09B , missing expectations by -2.48%.
Dividend declared on 27 Jun 2022
A dividend of $0.87 per share was announced, adjusted to $0.87. The dividend was paid on 23 Aug 2022.
Earnings released on 31 Dec 2021
EPS came in at $1.64 falling short of the estimated $1.80 by -8.89%, while revenue for the quarter reached $332.94B , missing expectations by -0.58%.
Earnings released on 30 Jun 2021
EPS came in at $1.38 surpassing the estimated $1.25 by +10.40%, while revenue for the quarter reached $299.10B , missing expectations by -0.37%.
Dividend declared on 15 Jun 2021
A dividend of $0.84 per share was announced, adjusted to $0.84. The dividend was paid on 10 Aug 2021.
Earnings released on 31 Dec 2020
EPS came in at $1.63 surpassing the estimated $1.62 by +0.62%, while revenue for the quarter reached $300.05B , beating expectations by +0.41%.
Earnings released on 22 Oct 2020
EPS came in at $1.02 falling short of the estimated $1.07 by -4.67%, while revenue for the quarter reached $223.67B , missing expectations by -5.03%.
1099.HK Stock Performance
Access detailed 1099.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.